文献速递心血管US

马瓦卡腾治疗梗阻性肥厚型心肌病患者长达128周的心脏重构长期改善:VALOR-HCM试验启示

Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for Up to 128 Weeks: Insights From the VALOR-HCM Trial.
PubMed 文献 · JACC Cardiovasc Imaging · 2025-09-16

VALOR-HCM试验纳入112例症状性梗阻性肥厚型心肌病患者,随机接受马瓦卡腾或安慰剂16周后均接受马瓦卡腾至128周。结果显示左室流出道压差、左室质量指数、E/e'、左室及左房应变等指标较基线持续改善,且与生活质量改善相关。

要点

  • 马瓦卡腾治疗128周可持续改善左室流出道压差、左室质量指数及左房左室应变。
  • KCCQ-23-CSS改善≥5分的患者左房左室应变显著改善,改善<5分者无显著改善。
  • 超声心动图评估应包括静息及负荷左室流出道压差、左室质量指数和整体纵向应变。

核心结论

  • 在VALOR-HCM试验中,马瓦卡腾治疗从基线至第128周持续带来有利的心脏重构,包括左室流出道压差、心脏容积、心肌肥厚、舒张功能及左房左室应变标志物的改善,提示疾病修饰作用,且这些有利变化与生活质量有意义的改善相关。

研究设计与样本

  • VALOR-HCM试验(NCT04349072)为随机对照试验,112例有症状的梗阻性肥厚型心肌病成人患者按1:1随机接受马瓦卡腾或安慰剂16周,随后安慰剂组转为马瓦卡腾治疗112周,原马瓦卡腾组治疗128周。

关键影像表现/征象

  • 第128周时左室流出道压差较基线持续改善:静息-61%、Valsalva动作后-72%、运动后-53%(均P<0.05)。
  • 第128周时左室质量指数较基线降低11%,室间隔E/e'降低18%,左室整体纵向应变改善4.5%(均P<0.05)。
  • 第128周时左房容积指数较基线降低6%,左房管道应变改善16%、收缩应变改善35%、储器应变改善32%(均P<0.05)。

诊断标准与关键数值

  • 在KCCQ-23-CSS改善≥5分的71例患者中,左房和左室应变值显著且持续改善(均P<0.05)。
  • 在KCCQ-23-CSS改善<5分的25例患者中,各项左房和左室应变值无显著改善。

临床应用与阅片要点

  • 对马瓦卡腾治疗的梗阻性肥厚型心肌病患者,超声随访应关注左室流出道压差(静息、Valsalva动作后、运动后)、左室质量指数、E/e'及左房左室应变。
  • 应变测量可采用供应商中立软件(TOMTEC-ARENA TTA2,Philips Healthcare)以评估左室和左房整体纵向应变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: In the VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy; NCT04349072) trial, patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten demonstrated significant improvement in left ventricular outflow tract (LVOT) gradients and echocardiographic indices of cardiac remodeling in the short term.

OBJECTIVES: The authors sought to assess whether mavacamten results in sustained favorable long-term cardiac remodeling at 128 weeks (end of trial).

METHODS: A total of 112 adult symptomatic obstructive HCM patients (mean age: 60.3 years; 50% men; and 94% NYHA functional class III/IV) who were referred for septal reduction therapy were randomized 1:1 to mavacamten or placebo for 16 weeks. Subsequently, placebo patients transitioned to and received 112 weeks of mavacamten, and the original mavacamten group received 128 weeks of mavacamten. All patients had comprehensive echocardiographic assessments (including LV and left atrial [LA] global longitudinal strain measurements using vendor neutral software [TOMTEC-ARENA TTA2, Philips Healthcare]) at baseline and 128-week follow-up.

RESULTS: At week 128, there was a sustained improvement (mean percentage of change from baseline, all P < 0.05) in LVOT gradients (resting [-61%], post-Valsalva [-72%], and postexercise [-53%]), LV mass index (-11%), septal E/e' (-18%), LV global longitudinal strain (4.5%), LA volume index (-6%), and LA strain (conduit strain [16%], contraction [35%], and reservoir [32%]). In 71 patients with ≥5 point improvement in the Kansas City Cardiomyopathy Questionnaire 23-item Clinical Summary Score (KCCQ-23-CSS), there was a significant and sustained improvement (all P < 0.05), whereas in 25 patients with <5 point improvement in the KCCQ-23-CSS, there was no significant improvement in various LA and LV strain values.

CONCLUSIONS: In the VALOR-HCM trial, treatment with mavacamten resulted in sustained favorable cardiac remodeling, including improvement in LVOT gradients, cardiac volumes, cardiac hypertrophy, diastolic function, and markers of LA and LV strain from baseline through week 128, suggesting disease modification. These favorable changes also occurred in association with meaningful improvement in quality of life.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Desai MY, Okushi Y, Wolski K, et al. Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for Up to 128 Weeks: Insights From the VALOR-HCM Trial. JACC Cardiovasc Imaging. 2025. PMID: 40956275. doi:10.1016/j.jcmg.2025.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。